Expects net cash used in operations to be less than $400M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
- Ultragenyx announces completion of enrollment in Phase 3 studies of setrusumab
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx price target raised to $61 from $59 at TD Cowen
- Ultragenyx initiated with an Outperform at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com